Antibody response to the malaria vaccine candidates CSP, LSA-3, AMA-1, MSP-1 and MSP-2 did not discriminate between protected and susceptible children in agreement with the previous study15, as well as with results of clinical trials of candidate AMA-128 and MSP-129 vaccines. The gene discussed is DNAJC5; the disease is malaria.